Health news this week is dominated by significant developments affecting the global landscape. Cyprus has implemented strict livestock controls following confirmed cases of foot-and-mouth disease, notably impacting farming operations on several fronts.
In the pharmaceutical realm, notable corporate moves include Frontier Biotechnologies’ substantial $1 billion collaboration with GSK, aimed at advancing kidney disease treatments and expanding market reach.
Meanwhile, Novo Nordisk faces market pressures as its obesity drug CagriSema fails to outperform a competitor, causing a dramatic reshaping of the company’s market valuation. These stories underscore the complex and dynamic environment within the health sector.
(With inputs from agencies.)